Literature DB >> 12152681

Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group.

Guido Reber1, Inger Schousboe, Angela Tincani, Marielle Sanmarco, Tanja Kveder, Philippe de Moerloose, Marie-Claire Boffa, Josiane Arvieux.   

Abstract

Inter-laboratory variability of anti-beta2-glycoprotein I antibody measurements (IgG and IgM) was investigated in the frame of the European Forum on Antiphospholipid Antibodies and its Standardization Group. Twenty-eight samples from patients with autoimmune diseases, two samples from blood donors and a set of six calibrators obtained by dilution with normal plasma of a pool of patient samples were sent to 21 European centers. Six of them used commercial kits and the others home-made assays. Marked differences in the steepness of the calibration curves obtained with the calibrator provided were observed. The standard deviations of sample measurement were high. Cut-off of positivity varied from 7 to 90 Forum Units (FU) for IgG and from 10 to 138 FU for IgM, whereas the rate of positivity varied from 50 to 93% for IgG and from 13 to 70% for IgM. No clear relationship between cut-off values and positivity rate could be established for either isotype. Adopting a common cut-off did not markedly improve the overall agreement between centers in positive/negative sample classification. Because of the majority of low positive samples, excellent concordance between centers (as defined by kappa values from 0.8 and 1) occurred only in 13% of cases for IgG and in 6% of cases for IgM, because many selected samples were low-positive. Despite the large variability of anti-beta2-glycoprotein I measurements between centers, the agreement on results with high- and medium-positive samples was good.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152681

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  Renal involvement in antiphospholipid syndrome.

Authors:  Guillermo J Pons-Estel; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

2.  Real world experience with antiphospholipid antibody tests: how stable are results over time?

Authors:  D Erkan; W J M Derksen; V Kaplan; L Sammaritano; S S Pierangeli; R Roubey; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

3.  Autoimmune reactivity of IgM acquired after oxidation.

Authors:  Jasna Omersel; Ivica Avberšek-Lužnik; Pegi Ahlin Grabnar; Tanja Kveder; Blaž Rozman; Borut Božič
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

Review 4.  [Antiphospholipid syndrome 2007. Current aspects of laboratory diagnostics and their therapeutic consequences].

Authors:  S Schuchmann; T Dörner
Journal:  Z Rheumatol       Date:  2007-05       Impact factor: 1.372

5.  Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss.

Authors:  A E Tebo; T D Jaskowski; H R Hill; D W Branch
Journal:  Clin Exp Immunol       Date:  2008-09-23       Impact factor: 4.330

6.  High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.

Authors:  S Cucnik; T Kveder; I Krizaj; B Rozman; B Bozic
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

7.  Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.

Authors:  Carole Ferraro-Peyret; Fabienne Coury; Jacques G Tebib; Jacques Bienvenu; Nicole Fabien
Journal:  Arthritis Res Ther       Date:  2004-09-23       Impact factor: 5.156

8.  Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs.

Authors:  Leonie Pelkmans; Hilde Kelchtermans; Philip G de Groot; Stephane Zuily; Veronique Regnault; Denis Wahl; Vittorio Pengo; Bas de Laat
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

Review 9.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

10.  Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study.

Authors:  Carlos J Bidot; Lawrence L Horstman; Wenche Jy; Joaquin J Jimenez; Carlos Bidot; Yeon S Ahn; J Steven Alexander; Eduardo Gonzalez-Toledo; Roger E Kelley; Alireza Minagar
Journal:  BMC Neurol       Date:  2007-10-18       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.